Literature DB >> 19622386

Decreased behavioral impairments in an Alzheimer mice model by interfering with TNF-alpha metabolism.

Fabienne Giuliani1, André Vernay, Geneviève Leuba, Françoise Schenk.   

Abstract

The performance of mice expressing PDAPP (+/+ or +/-) was studied in the Morris place navigation task. Different lines of questions were investigated using PDAPP+/- mice in which the activity of the cytokine Tumor Necrosing Factor alpha (TNFalpha) was attenuated by chronic treatment with anti-TNF or deleting TNFalpha (TNF-/-). Two different categories of behavior were analyzed in adult (6 months) and middle aged (15 months) subjects. Classically, the cognitive performance was assessed from the escape efficacy and quantitative bias toward the training position in a Morris water maze. Second, stereotyped circling was quantified, along with more qualitative behavioral impairments such as self-mutilation or increased reactivity. Our results can be summarized as follows. (1) All of the PDAPP mice expressed reduced cognitive performance in the Morris task, but only those with a clear-cut amyloid burden in the hippocampus showed behavioral abnormalities such as stereotyped circling. (2) Chronic treatment with anti-TNF prevented the development of pathological circling in the 6-month-old mice but not in the 15-month-old mice and had no significant effect on amyloid burden. (3) The absence of TNFalpha prevented the development of stereotyped circling in 6- and 15-month-old mice but increased amyloid burden after 15 months. These data indicate that PDAPP mice express cognitive impairments disregarding absence of TNF. The pathological behavioral anomalies related to the PDAPP mutation seem reduced by treatments interfering with TNFalpha.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19622386     DOI: 10.1016/j.brainresbull.2009.07.009

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  20 in total

Review 1.  Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system.

Authors:  Sara L Montgomery; William J Bowers
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-05       Impact factor: 4.147

2.  Maternal immune markers during pregnancy and child neurodevelopmental outcomes at age 20 months in the Seychelles Child Development Study.

Authors:  Jessica L Irwin; Emeir M McSorley; Alison J Yeates; Maria S Mulhern; J J Strain; Gene E Watson; Katherine Grzesik; Sally W Thurston; Tanzy M Love; Tristram H Smith; Karin Broberg; Conrad F Shamlaye; Gary J Myers; Philip W Davidson; Edwin van Wijngaarden
Journal:  J Neuroimmunol       Date:  2019-08-14       Impact factor: 3.478

3.  Atorvastatin prevents amyloid-β peptide oligomer-induced synaptotoxicity and memory dysfunction in rats through a p38 MAPK-dependent pathway.

Authors:  Ling-Ling Zhang; Hai-Juan Sui; Bing Liang; Han-Ming Wang; Wen-Hui Qu; Sheng-Xue Yu; Ying Jin
Journal:  Acta Pharmacol Sin       Date:  2014-05-05       Impact factor: 6.150

4.  Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model.

Authors:  Masashi Kitazawa; David Cheng; Michelle R Tsukamoto; Maya A Koike; Paul D Wes; Vitaly Vasilevko; David H Cribbs; Frank M LaFerla
Journal:  J Immunol       Date:  2011-11-16       Impact factor: 5.422

5.  Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept.

Authors:  Edward Tobinick; Nancy M Kim; Gary Reyzin; Helen Rodriguez-Romanacce; Venita DePuy
Journal:  CNS Drugs       Date:  2012-12       Impact factor: 5.749

6.  Association between high levels of inflammatory markers and cognitive outcomes at 4 years of age: The Rhea mother-child cohort study, Crete, Greece.

Authors:  Andriani Kyriklaki; Katerina Margetaki; Mariza Kampouri; Katerina Koutra; Panos Bitsios; Georgia Chalkiadaki; Eirini Dermitzaki; Maria Venihaki; Katerina Sarri; Despoina Anousaki; Manolis Kogevinas; Leda Chatzi
Journal:  Cytokine       Date:  2019-02-14       Impact factor: 3.861

Review 7.  Implications of gliotransmission for the pharmacotherapy of CNS disorders.

Authors:  Daniela Rossi; Francesca Martorana; Liliana Brambilla
Journal:  CNS Drugs       Date:  2011-08       Impact factor: 5.749

8.  A single intraperitoneal injection of endotoxin in rats induces long-lasting modifications in behavior and brain protein levels of TNF-α and IL-18.

Authors:  Paola Bossù; Debora Cutuli; Ilaria Palladino; Paola Caporali; Francesco Angelucci; Daniela Laricchiuta; Francesca Gelfo; Paola De Bartolo; Carlo Caltagirone; Laura Petrosini
Journal:  J Neuroinflammation       Date:  2012-05-29       Impact factor: 8.322

9.  Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease.

Authors:  S Prasad Gabbita; Minu K Srivastava; Pirooz Eslami; Ming F Johnson; Naomi K Kobritz; David Tweedie; Nigel H Greig; Frank P Zemlan; Sherven P Sharma; Marni E Harris-White
Journal:  J Neuroinflammation       Date:  2012-05-25       Impact factor: 8.322

10.  Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis.

Authors:  Do Young Kim; Junwei Hao; Ruolan Liu; Gregory Turner; Fu-Dong Shi; Jong M Rho
Journal:  PLoS One       Date:  2012-05-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.